James C Mullen - Net Worth and Insider Trading

James C Mullen Net Worth

The estimated net worth of James C Mullen is at least $30 Million dollars as of 2024-11-06. James C Mullen is the CEO & President of Biogen Inc and owns about 131,149 shares of Biogen Inc (BIIB) stock worth over $23 Million. James C Mullen is the Director of Revvity Inc and owns about 45,551 shares of Revvity Inc (RVTY) stock worth over $6 Million. James C Mullen is also the Director of Insulet Corp and owns about 5,598 shares of Insulet Corp (PODD) stock worth over $1 Million. Besides these, James C Mullen also holds Editas Medicine Inc (EDIT) . Details can be seen in James C Mullen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that James C Mullen has not made any transactions after 2021-10-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of James C Mullen

To

James C Mullen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, James C Mullen owns 6 companies in total, including Editas Medicine Inc (EDIT) , Thermo Fisher Scientific Inc (TMO) , and Insulet Corp (PODD) among others .

Click here to see the complete history of James C Mullen’s form 4 insider trades.

Insider Ownership Summary of James C Mullen

Ticker Comapny Transaction Date Type of Owner
EDIT Editas Medicine Inc 2021-10-18 director
TMO Thermo Fisher Scientific Inc 2018-11-07 director
PODD Insulet Corp 2017-11-13 director
LIMIT LIMIT 2017-08-29 director & Chief Executive Officer
LIMIT LIMIT 2014-11-14 director
LIMIT LIMIT 2010-03-22 director & CEO & President

James C Mullen Latest Holdings Summary

James C Mullen currently owns a total of 4 stocks. Among these stocks, James C Mullen owns 131,149 shares of Biogen Inc (BIIB) as of March 22, 2010, with a value of $23 Million and a weighting of 76.15%. James C Mullen owns 45,551 shares of Revvity Inc (RVTY) as of November 14, 2014, with a value of $6 Million and a weighting of 18.83%. James C Mullen also owns 5,598 shares of Insulet Corp (PODD) as of November 13, 2017, with a value of $1 Million and a weighting of 4.43%. The other 1 stocks Editas Medicine Inc (EDIT) have a combined weighting of 0.59% among all his current holdings.

Latest Holdings of James C Mullen

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BIIB Biogen Inc 2010-03-22 131,149 176.93 23,204,193
RVTY Revvity Inc 2014-11-14 45,551 125.96 5,737,604
PODD Insulet Corp 2017-11-13 5,598 241.32 1,350,909
EDIT Editas Medicine Inc 2021-10-18 57,673 3.12 179,940

Holding Weightings of James C Mullen


James C Mullen Form 4 Trading Tracker

According to the SEC Form 4 filings, James C Mullen has made a total of 0 transactions in Biogen Inc (BIIB) over the past 5 years. The most-recent trade in Biogen Inc is the sale of 440,500 shares on March 22, 2010, which brought James C Mullen around $26 Million.

According to the SEC Form 4 filings, James C Mullen has made a total of 0 transactions in Revvity Inc (RVTY) over the past 5 years. The most-recent trade in Revvity Inc is the sale of 8,892 shares on November 14, 2014, which brought James C Mullen around $388,847.

According to the SEC Form 4 filings, James C Mullen has made a total of 0 transactions in Insulet Corp (PODD) over the past 5 years. The most-recent trade in Insulet Corp is the acquisition of 2,500 shares on November 13, 2017, which cost James C Mullen around $168,625.

More details on James C Mullen's insider transactions can be found in the Insider Trading History of James C Mullen table.

Insider Trading History of James C Mullen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

James C Mullen Trading Performance

GuruFocus tracks the stock performance after each of James C Mullen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by James C Mullen is -10.89%. GuruFocus also compares James C Mullen's trading performance to market benchmark return within the same time period. The performance of stocks bought by James C Mullen within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how James C Mullen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of James C Mullen

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 4.04 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 1.09 LIMIT LIMIT LIMIT LIMIT LIMIT

James C Mullen Ownership Network

Ownership Network List of James C Mullen

No Data

Ownership Network Relation of James C Mullen

Insider Network Chart

James C Mullen Owned Company Details

What does Editas Medicine Inc do?

Who are the key executives at Editas Medicine Inc?

James C Mullen is the director of Editas Medicine Inc. Other key executives at Editas Medicine Inc include SVP & CHIEF MEDICAL OFFICER Baisong Mei , director & CEO Gilmore Neil O'neill , and EVP & CHIEF SCIENTIFIC OFFICER Linda Burkly .

Editas Medicine Inc (EDIT) Insider Trades Summary

Over the past 18 months, James C Mullen made no insider transaction in Editas Medicine Inc (EDIT). Other recent insider transactions involving Editas Medicine Inc (EDIT) include a net sale of 2,791 shares made by Bruce Eaton , a net sale of 32,292 shares made by Baisong Mei , and a net sale of 98,056 shares made by Gilmore Neil O'neill .

In summary, during the past 3 months, insiders sold 2,073 shares of Editas Medicine Inc (EDIT) in total and bought 0 shares, with a net sale of 2,073 shares. During the past 18 months, 168,311 shares of Editas Medicine Inc (EDIT) were sold and 45,000 shares were bought by its insiders, resulting in a net sale of 123,311 shares.

Editas Medicine Inc (EDIT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Editas Medicine Inc Insider Transactions

No Available Data

James C Mullen Mailing Address

Above is the net worth, insider trading, and ownership report for James C Mullen. You might contact James C Mullen via mailing address: 940 Winter Street, Perkinelmer, Inc Legal Department, Waltham Ma 02451.